Polypill
The polypill , loosely translated as "medicament for a lot / from a lot", is an English name for a tablet that contains various medicinal substances in low doses . Given in this composition daily and as a preventive measure for a long time, the Polypill is said to reduce the risk of cardiovascular diseases . At the same time, the dosage of the ingredients is chosen so that side effects should be as low as possible. This concept for prevention has been discussed since 2003, in particular cost-benefit considerations and risk assessments play a role.
composition
The "Polypill" should contain the following low-dose active ingredients:
Circulatory active substances to lower blood pressure :
In combination with:
- Statin , cholesterol lowering drug
- ASS
- Folic acid to lower homocysteine levels
Regardless of a pre-existing risk, these active ingredients are intended to lower cholesterol , lower blood pressure, lower homocysteine and inhibit the blood clotting of blood platelets using ASA. This combination should offer a chance of life extension with a side effect frequency of about 10%. Quote: It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than any other single intervention.
Whether this concept of the polypill is accepted is the subject of research. The WHO supports these studies, among other things, because it may be a useful approach for populous emerging countries.
In July 2015, a preparation based on the Polypill concept came onto the market in Germany. It contains a fixed combination of acetylsalicylic acid , atorvastatin and ramipril and is the first preparation in Germany that combines different principles of action for the prevention of cardiovascular events. It is designed to improve adherence to therapy in patients who must take many drugs .
Similar concept
A similar approach is being pursued with the concept of the polymeal . This is a special form of diet that promises to extend life by a few years.
Individual evidence
- ↑ Peter Sleight *, Hubert Pouleur, Faiez Zannad: Benefits, challenges, and registerability of the polypill, European Heart Journal 2006 27 (14): 1651-1656.
- ^ NJ Wald, MR Law,: A strategy to reduce cardiovascular disease by more than 80% in BMJ 2003; 326: 1419.
- ↑ K. Srinath Reddy, The Preventive Polypill - Much Promise, Insufficient Evidence in NEJM , Volume 356: 212 January 18, 2007 No. 3.
- ^ Oscar H Franco, Luc Bonneux, The limits of medicine: The Polymeal, BMJ 2004; 329: 1447-1450 (December 18).
